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Introduction
Neuroacanthocytosis refers to a group of inherited genetic disorders resulting in a combination of misshapen red
blood cells (acanthocytes) and progressive neurological decline.[1] The neurological presentation can vary widely
among diseases and can include shared characteristic features of movement disorders, neuropathy, psychiatric
symptoms, neurocognitive degeneration, and seizures.[2] Specific diseases are many, including chorea-acanthocytosis
(ChAc),[3] McLeod syndrome (MLS),[4] Huntington like-disease 2 (HDL2),[5] pantothenate kinase-associated
neurodegeneration (PKAN, also known as Hallervorden Spatz disease),[6][7] HARP Syndrome (considered part of
the PKAN spectrum consisting of hypoprebetalipoproteinemia, acanthocytosis, retinitis pigmentosa, and pallidal
degeneration), abetalipoproteinemia (ABL),[8] hereditary hypobetalipoproteinemia (HHBL),[9] and
aceruloplasminemia.[10][11] The two core conditions are chorea-acanthocytosis and McLeod Syndrome. Each
neuroacanthocytosis disorder is extremely rare, with a prevalence of less than 1 to 3 per 1,000,000 individuals for
PKAN or fewer than 100 cases ever reported in the case of ABL.
Etiology
Neuroacanthocytosis syndromes are caused by a variety of genetic mutations that are inherited in several different
patterns, with the most common being autosomal recessive (see Tables 1 & 2). Other syndromes such as McLeod
syndrome are inherited in an X-linked recessive pattern, whereas Huntington like-disease 2 and hereditary
hypobetalipoproteinemia are inherited in autosomal dominant and codominant patterns, respectively. HDL2 directly
results from trinucleotide expansions of JPH3 very similarly to Huntington disease with patients experiencing
intergenerational disease anticipation based on the extent of genetic expansion. Many of these diseases vary in genetic
penetrance and phenotypic manifestations.[3][4][5][6][8][9][10]
Epidemiology
Each neuroacanthocytosis syndrome is exceedingly rare (see Table 1). Several populations have been identified as
having higher prevalence compared to the global population. Examples include HDL2 demonstrating increased
reported cases among individuals of African heritage and PKAN occurring more often in small pockets in the
Netherlands and the Dominican Republic.[5]
Pathophysiology
The pathophysiology of these syndromes is unique to each and can vary widely in phenotypic disease manifestation
(see Table 2). The direct cellular mechanisms of several syndromes such as PKAN, aceruloplasminemia, and diseases
of lipoproteins are understood and described in the current literature. These syndromes tend to have better outcomes
either due to milder disease progression or treatment modalities that prevent significant mortality and morbidity.[6][8]
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genes.[3][4][5] These diseases tend to be much more chronically debilitating and are not uniformly responsive
to attempted treatments that have been sparsely reported.
History and Physical
Nearly all patients affected by neuroacanthocytosis syndromes will experience the eventual onset of progressive
abnormalities in movement (usually ataxia or hyperkinetic movements) with a neurocognitive decline and behavioral
changes (see Table 3). Each specific disease, however, may present with symptoms and comorbidities unique to the
disease. If the clinician possesses significant clinical suspicion of a neuroacanthocytosis syndrome, a thorough
physical exam is required. This would include a complete physical and neurological examination, including reflexes,
cranial nerves, gait, muscle strength, and mental status exams.
A clear history of progressive neurological, neuromuscular, or neuropsychiatric symptoms that are not consistent with
other more common diseases plays an integral role in identifying these rare syndromes as possible diagnoses. The
acquisition of prior records, family history, collateral history, and any prior genetic testing may prove instrumental in
establishing accurate differential diagnoses and choosing clinically appropriate diagnostic modalities for further
evaluation.
Evaluation
For many of these syndromes, the clinical symptoms will often prompt the use of additional diagnostic modalities that
are instrumental in establishing a correct diagnosis (see Table 4). Such modalities include magnetic resonance
imaging (MRI), or computed tomography (CT) scans to assess neurological involvement in the cerebral or spinal
nervous tissues. Additionally, laboratory testing of serum samples may be useful in ruling out some diseases while
providing confirmatory data for others, as in the case of the diseases of lipoproteins (ABL and HHBL) or
aceruloplasminemia. For most neuroacanthocytosis syndromes, there are either no clear diagnostic criteria (e.g.,
ChAc, ABL, and HHBL) or genetic testing to identify diseases that may otherwise be indistinguishable from other
syndromes (e.g., HDL2).
Treatment / Management
There is no cure or definitive treatment for several of the neuroacanthocytosis syndromes, such as ChAc and MLS
(see Table 5).[12] With the exception of ABL, HHBL, and aceruloplasminemia, the goals of management generally
are to:
1) Treat symptomatically
2) Slow the development of progressive symptoms
3) Evaluate for and prevent where possible serious causes of morbidity and mortality such as ophthalmic
involvement, metabolic/hormonal imbalances, seizures, cardiac involvement, and status dystonicus.
Interprofessional treatment teams have been advocated as the ideal approach in caring for patients who likely have
complex and significant symptoms that run the gamut of neurological to psychiatric to multiple organ systems.[12]
Consultation by medical specialists in neurology, psychiatry, neuropsychiatry, ophthalmology, or clinical genetics may
be appropriate in identifying, evaluating, and managing patients diagnosed with neuroacanthocytosis syndromes (see
Table 6).
Differential Diagnosis
The differential diagnoses for these rare syndromes are many and sometimes may be indistinguishable from other
disease entities without the appropriate radiological, laboratory, or genetic workup (see Table 7).
Pertinent Studies and Ongoing Trials
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Due to the extreme rarity of these syndromes, there have been no randomized control trials or experimental treatment
studies assessing the efficacy of diagnostic or treatment modalities.[12][13][14] Information regarding diagnostic
criteria and possible treatments have been largely developed from the aggregation of case reports and case series.[12]
Toxicity and Side Effect Management
There are several side effects to keep in mind for several specific syndromes and their associated management (see
Table 5). For example, antiepileptic drugs (AEDs) such as carbamazepine and lamotrigine should be avoided in
patients with ChAc due to the worsening of involuntary movements.[3] Conversely, long-term use of benzodiazepines
should be avoided as an AED in patients with McLeod syndrome due to potential negative effects on the
neuromuscular system. Additionally, dopamine antagonists or tetrabenazine should be avoided due to increased risk
of extrapyramidal symptoms (EPS) in MLS patients.[4]
Another consideration for MLS patients is to avoid heterologous blood product transfusions due to an increased risk
of adverse transfusion reactions. Case reports have suggested avoiding alpha-tocopherol and idebenone in treating the
neuromuscular symptoms of patients with PKAN due to anecdotal evidence suggesting worsening of symptoms.[6]
Finally, patients should avoid iron supplementation or other sources of exogenous iron due to the iron accumulation
inherent in the disease.[10]
Prognosis
The prognosis for these syndromes is variable. Syndromes such as ChAc, MLS, typical PKAN, and HDL2 are known
to be chronic and progressive, often resulting in complications of dysarthria such as malnutrition and aspiration
pneumonia with eventual death (see Table 8). In some cases, complicating symptoms such as seizures, cardiac
arrhythmias, cardiomyopathy, and status dystonicus may cause premature death. On the other hand, the mortality and
progression of aceruloplasminemia, ABL, and HHBL are heavily influenced by appropriate management with
chelating agents and fat-soluble vitamin supplementation (respectively) with patients enjoying a typical lifespan if
managed appropriately.[8][9][10]
Complications
Many of the complications arising from neuroacanthocytosis syndromes derive from neuromuscular deficits or
neurocognitive decline (see Table 3). Neuromuscular symptoms such as chorea, ataxia, myopathy, dystonia, loss of
dorsal column, or spinocerebellar spinal tracts can result in gait disturbances and inability to participate in ADLs.
Additional progressive cognitive deficits or personality changes (including increased impulsivity, aggression, or
psychiatric symptoms) can further complicate care for patients diagnosed with a neuroacanthocytosis syndrome.
Several complications can be life-threatening, including seizures, cardiac arrhythmias, cardiomyopathy, status
dystonicus, and psychiatric comorbidities such as suicidality.
Ophthalmological complications such as retinal degeneration and retinopathy are commonly described in cases of
PKAN, ABL, HHBL, and aceruloplasminemia. In the case of several metabolically driven diseases such as ABL,
HHBL, and aceruloplasminemia, multiple organ systems can be involved resulting in anemia, diabetes mellitus,
cardiomegaly, hepatosplenomegaly, and hypothyroidism.
Deterrence and Patient Education
Genetic counseling plays an important role in the management as well as appropriate evaluation and education for
both the patient and involved family members. Consultation with a genetic counselor and clinical geneticist can
provide important clinical information such as genotypic and phenotypic characteristics of the disease, possible
disease progression, and the likelihood of disease occurring in relatives or offspring.[1]
Enhancing Healthcare Team Outcomes














Recent literature advocates interprofessional team-based care as the ideal approach in caring for patients diagnosed
with neuroacanthocytosis syndromes due to the severity and chronic progression of symptoms as well as possible
development of severe medical comorbidity.[12] Such a care team would likely consist of the patient's primary care
clinician, neurologist, clinical geneticist (or genetic counselor), and several other therapeutic modalities (see Table 5).
Providers may seek additional care in consultation with specialists in psychiatry, ophthalmology, and cardiology in
diseases such as MLS, PKAN, and ABL/HHBL. The extreme rarity of these syndromes significantly limits evidence-
based treatments. Patients with these syndromes may require involved and prolonged team-based care to improve
symptoms and prevent the development of serious medical complications.
Continuing Education / Review Questions
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Figures
Table 1: Epidemiology of Neuroacanthocytosis Syndromes Table 2: Genetics of Neuroacanthocytosis Syndromes.
Contributed by Joshua Feriante DO, MBA
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Table 3: Clinical Manifestations of Neuroacanthocytosis Syndromes. Contributed by Joshua Feriante DO, MBA
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Table 4: Diagnostic Testing for Neuroacanthocytosis Syndromes. Contributed by Joshua Feriante DO, MBA
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Table 5: Management, Preventive Measures, and Multi-disciplinary Team Involvement for Neuroacanthocytosis
Syndromes Table 6: Preventive Measures and Multi-disciplinary Team Involvement for Neuroacanthocytosis
Syndromes. Contributed by Joshua Feriante DO, MBA
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Table 7: Differential Diagnoses for Neuroacanthocytosis Syndromes Table 8: Prognoses of Neuroacanthocytosis
Syndromes. Contributed by Joshua Feriante DO, MBA
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